Innovation Strategy Development
Product Lifecycle Management
Technology Scouting and Assessment
Process Optimization
Prototyping and Testing
Regulatory Compliance and Risk Management
Intellectual Property Management
Collaborative Research Partnerships
Data Analytics and Insights
Training and Development Programs for R&D Teams
Quality Assurance and Control
Sustainable R&D Practices
Project Management for R&D Initiatives
Customer-Centric R&D Approaches
Market and Trend Analysis
Design for Six Sigma
We are at the forefront of scientific discovery, dedicated to transforming the landscape of drug discovery and understanding the molecular basis of aging and disease. Our research integrates cutting-edge high-throughput technologies with advanced computational biology approaches to unravel complex biological mechanisms and identify novel therapeutic targets. Through an interdisciplinary strategy that combines biology, engineering, and machine learning, we aim to develop targeted interventions for some of the most pressing health challenges, including neurodegeneration, cardiovascular diseases, and metabolic disorders.
Our research program is designed to uncover the molecular pathologies driving disease and the cellular changes regulated by these pathological states. We leverage a multi-model organism approach to conduct high-throughput genetic and metabolic screenings in a wide range of systems and disease models, including budding yeast (*Saccharomyces cerevisiae*), nematode worm (*C. elegans*), and mammalian cell cultures (mouse and human). By studying these evolutionarily conserved models, we aim to identify genetic and metabolic regulators that influence lifespan, stress resistance, and disease progression. Our research strategy provides a powerful framework for identifying potential pharmacological targets and understanding the mechanistic basis of cellular aging and disease.
Our laboratory is equipped with state-of-the-art high-throughput platforms that enable large-scale screening and validation of drug candidates and drug targets. Through microfluidic chambers and cutting-edge technologies, we can precisely control environmental conditions and monitor cellular responses in real time. Automated lifespan and healthspan assays allow us to measure the effects of genetic and chemical interventions with high precision. In addition, behavioral assays in model organisms enable us to assess functional outcomes, providing a direct link between molecular changes and organismal health. Our ability to integrate next-generation sequencing and multi-omics data into these platforms further enhances our capacity to identify biomarkers and drug targets.
In parallel with our experimental approaches, we employ powerful computational biology and machine learning techniques to analyze complex biological datasets. Our machine learning-based drug docking and target prediction models allow us to identify promising small molecules and predict their molecular targets with high accuracy. By integrating multi-omics data, we reconstruct genetic and metabolic networks to uncover hidden relationships and mechanistic pathways. Predictive modeling enables us to simulate drug-target interactions and disease progression, providing insights into the most effective intervention strategies. This comprehensive computational approach ensures that our discoveries are data-driven and mechanistically sound.
Our ultimate goal is to translate fundamental discoveries into clinical applications. By identifying conserved genetic and metabolic regulators, we aim to develop targeted therapies for age-associated diseases such as neurodegeneration, cancer, and cardiovascular diseases, as well as metabolic disorders like diabetes. Our approach involves a systematic pipeline of discovery, validation, and preclinical testing, ensuring that promising interventions are rigorously evaluated for their efficacy and safety. Our research not only provides new insights into the biology of aging and disease but also lays the groundwork for next-generation therapeutic strategies.
We have established a strong network of collaborative partnerships with leading academic institutions and pharmaceutical companies. Our interdisciplinary research environment fosters innovation and accelerates the transition from discovery to clinical application. We actively seek to engage with new partners to expand our research capacity and bring innovative therapies to patients faster. Through continued investment in cutting-edge technologies and strategic collaborations, we are poised to lead the next wave of discoveries in aging biology and drug development against metabolic and genetic diseases.
We are not just a research laboratory—it is a hub of scientific innovation where biology, technology, and computation converge to tackle some of the most challenging questions in health and disease. We welcome inquiries from potential collaborators, industry partners, and funding agencies to join us in this exciting journey toward better health and longer lives.
